In an analyst call, Merck EVP and CFO Peter Kellogg said the company plans "continued DTC efforts for Singulair and Januvia as well as appropriate promotional support for Gardasil, RotaTeq and Zostavax," along with support for the launch of Isentress and hopeful Cordaptive.
In an analyst call, Merck EVP and CFO Peter Kellogg said thecompany plans “continued DTC efforts for Singulair and Januvia as well asappropriate promotional support for Gardasil, RotaTeq and Zostavax,” along withsupport for the launch of Isentress and hopeful Cordaptive.
From the January 01, 2008 Issue of MM+M - Medical Marketing and Media
Get the most out of 
Register for free and enjoy unlimited access to:
